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Abstract 1 
 2 
Background: As a reference laboratory for HbA1c it is essential to have accurate and 3 
precise HbA1c methods covering a range of measurement principles. We report an 4 
evaluation of the Abbott Enzymatic (Architect c4000), Roche Gen.3 HbA1c (Cobas 5 
c513) and Tosoh G11 using different quality targets. 6 
Methods: The effect of haemoglobin variants, other potential interferences and the 7 
performance in comparison to both the International Federation of Clinical Chemistry 8 
and Laboratory Medicine (IFCC) and National Glycohemoglobin Standardization 9 
Program (NGSP) reference systems, was assessed using certified evaluation 10 
protocols.  11 
Results:  Each of the evaluated HbA1c methods had CVs <3% in SI units and <2% in 12 
NGSP units at 46 mmol/mol (6.4%) and 72 mmol/mol (8.7%) and passed the NGSP 13 
criteria when compared with 6 Secondary Reference Measurement Procedures 14 
(SRMP). Sigma was 8.6 for Abbott Enzymatic, 3.3 for Roche Cobas c513 and 6.9 for 15 
Tosoh G11. No clinically significant interference was detected for the common Hb-16 
variants for the 3 methods. 17 
Conclusion: All 3 methods performed well and are suitable for clinical application in 18 
the analysis of HbA1c. Partly based on the result of this study the Abbott Enzymatic 19 
method on the Architect c4000 and the Roche Gen.3 HbA1c on the Cobas c513 are 20 
now official, certified IFCC and NGSP SRMPs in the IFCC and NGSP networks. 21 
Sigma metrics quality criteria, presented in a graph distinguish between good and 22 
excellent performance. 23 
 24 
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Introduction 1 
Diabetes represents a huge global health burden and is a leading cause of morbidity 2 
and mortality worldwide [1].It is estimated that up to 50% of people with diabetes are 3 
currently undiagnosed, and this is a particular issue in hard to reach settings such as 4 
rural communities. The ability to identify and effectively treat people with diabetes is 5 
dependent on accurate and timely diagnostic testing, most commonly provided by 6 
hospital clinical laboratories, using a range of methods.  7 
Recently the World Health Organization advocated the use of HbA1c testing for the 8 
diagnosis of Type 2 diabetes however, there must be stringent quality control 9 
procedures in place to ensure accurate and precise test results and methods must be 10 
aligned to the international reference measurement procedure [2].  11 
Whilst the Diabetes Control and Complications Trial (DCCT) and UK Prospective 12 
Diabetes Study (UKPDS) were seminal trials of the time, more recently treatment 13 
targets for people with diabetes have become more individualised with the needs of 14 
the patient at the core of decision making [3]. With a patient centred approach it is 15 
essential that methods for detecting and monitoring diabetes are both accurate and 16 
precise to enable high quality, consistent care.  17 
The IFCC Task Force on Implementation of HbA1c standardization (TF-HbA1c) 18 
recently advocated sigma-metrics as the model of choice to set and evaluate quality 19 
targets for HbA1c [4]. In the laboratory sigma-metrics is a quality management 20 
strategy that provides a universal benchmark for process performances. Sigma-21 
metrics places analytical characteristics (bias and imprecision) within the framework 22 
of clinical requirements (Total Allowable Error (TAE)). The risk is defined in sigma 23 
units: a sigma of 2 implies a 5% risk to fail the TAE. The TF-HbA1c has set default 24 
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risk levels of 2σ for routine laboratories and 4σ for laboratories performing clinical 1 
trials [4]. These targets can be universally applied to commercially available HbA1c 2 
methods, with comparison to the IFCC Primary Reference Measurement Procedure 3 
(PRMP) via the SRMPs as the correct way to determine bias. 4 
The European Reference Laboratory for Glycohemoglobin (ERL) is responsible for 5 
the production of IFCC secondary reference material which enables manufacturers to 6 
be traceable to the IFCC PRMP and thus meet the requirement of the WHO and 7 
international consensus for the global standardisation of HbA1c. Currently the ERL 8 
consists of 7 IFCC certified and  5 NGSP certified SRMPs for the determination of 9 
HbA1c in 2 laboratories and is therefore able to evaluate any new HbA1c method at 10 
the highest level [5, 6].  11 
The aim of this paper was to evaluate the Roche Gen.3 Tina-quant HbA1c method on 12 
the Cobas c513 and the Abbott Architect Enzymatic method on the Architect c4000 13 
for adoption by the IFCC and NGSP reference networks as certified SRMPs using 14 
international quality targets. Beside these 2 methods, we also evaluated the Tosoh 15 
G11.  16 
 17 
Material and methods 18 
Abbott Enzymatic method on the Architect c4000 (Abbott Enzymatic)  19 
The Architect c4000 is a routine chemistry analyzer with photometric, potentiometric 20 
and turbidimetric methods available. The instrument is not specifically dedicated to 21 
HbA1c and has a maximum sample throughput of up to 800 tests per hour. The total 22 
run-time for HbA1c is 10 minutes. The enzymatic method principle has been 23 
described before and consists of two separate steps: measurement of glycated 24 
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dipeptide, obtained by enzymatic cleavage, and measurement of total hemoglobin [7, 1 
8]. Samples can be run using either the whole blood mode or the hemolysate mode, 2 
if there is not sufficient whole blood available, using a manual pre-dilution step. The 3 
instrument does not have closed tube sampling. 4 
The reagents are ready for use (350 tests per reagent cartridge) and are stable for 50 5 
days onboard the instrument which needs calibration every 50 days provided there is 6 
no change of reagent lot number.  During the precision study three different reagent 7 
lot numbers were used so the instrument was calibrated 3x using a single calibrator 8 
lot number.   9 
 10 
Roche Tina-quant Gen.3 on Cobas c513 (Roche c513) 11 
The Cobas c513 is the successor of the Integra 800 and is a fully dedicated instrument 12 
for HbA1c. The sample throughput is 400 patient results per hour which doubles the 13 
throughput compared with the Integra 800. The ready to use reagent is available in a 14 
large kit size (500 test per reagent cartridge) suitable for handling high workloads.  15 
The HbA1c determination is based on a turbidimetric inhibition immunoassay (TINIA) 16 
for hemolyzed whole blood. Total hemoglobin is measured bichromatically during the 17 
preincubation phase of the immunological reaction. Samples can be run using the 18 
whole blood mode with closed tubes sampling and the hemolysate mode for small 19 
blood volumes [9].  20 
Onboard stability of the reagent is 4 weeks. The method needs to be calibrated every 21 
28 days or when there is change of reagent lot number.  The calibration is a reagent 22 
lot specific, which means that not every calibrator can be used with the same values 23 
for every reagent lot. During the precision study the instrument was calibrated 3x using 24 
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the same lot number for the calibrator and reagent. During the method comparison 1 
study the instrument was calibrated once using the same lot number for the calibrator 2 
and the reagent. 3 
 4 
Tosoh G11  5 
The Tosoh HLC-723G11 variant mode (software version V02.00) uses cation 6 
exchange HPLC to separate hemoglobin components by different ionic charge. The 7 
various fractions of hemoglobin, including HbA1c, are quickly (30 seconds per 8 
sample) separated into 6 peaks and assayed. A step gradient of three different salt 9 
concentrations is used for peak separation and elution. The Tosoh G11 is the 10 
successor of the Tosoh G8 and has a reduced run time of 60 seconds. As a direct 11 
result of the shortened run time there is no longer a specific Hb-variant window. The 12 
G11 only has a H-VO window (HbAD, HbAS, HbAC all appear in this window), P-HV3 13 
(HbAE) and POO (for Unknown Hb-variants).  14 
The reagents are stable for 90 days after opening. The instrument requires 15 
calibration every 30 days. During the precision and method comparison study the 16 
instrument was calibrated once. Only one lot number of reagent and calibrator was 17 
used.  18 
Precision study 19 
Two samples with an HbA1c value of approximately 48 mmol/mol (6.5%) and 75 20 
mmol/mol (9.0%) were used, according to the CLSI EP-5 protocol (duplicate 21 
measurements twice per day for 20 days), to investigate assay imprecision. Aliquots 22 
were made from patient samples and stored at minus 80 °C until analysis [10]. 23 
Method comparison  24 
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The CLSI EP-9 protocol was performed with 80 frozen samples with HbA1c values over 1 
a clinically relevant range (27 mmol/mol (4.6%) to 86 mmol/mol (10.0% )) and the data 2 
were used to investigate the bias between the investigated methods and 6 IFCC and 3 
NGSP SRMPs (n=80, 16 samples per day for 5 days, duplicate measurements) [11]. 4 
HbA1c value assignment for the patient samples was performed with 6 IFCC SRMPs 5 
(4 of which are also NGSP SRMPs): 6 
Isala, Zwolle 7 
• Roche Tina-quant Gen.2 HbA1c on Integra 800, immunoassay, IFCC and NGSP 8 
certified (Roche Diagnostics, Rotkreuz, Switzerland) 9 
• Premier Hb9210, affinity chromatography HPLC, IFCC and NGSP certified 10 
(Trinity Biotech, Bray, Ireland) 11 
• Tosoh G8, cation-exchange HPLC, IFCC certified (Tosoh Bioscience, 12 
Tessenderlo, Belgium). 13 
Queen Beatrix Hospital, Winterswijk 14 
• Premier Hb9210, affinity chromatography HPLC, IFCC certified (Trinity Biotech, 15 
Bray, Ireland) 16 
• Menarini HA8180V, cation-exchange HPLC, IFCC  and NGSP certified 17 
(Menarini Diagnostics, Florence, Italy) 18 
• Sebia Capillarys 2 Flex Piercing, IFCC and NGSP certified (Sebia, Paris, 19 
France). 20 
To check bias, independently of the chosen SRMP, the results of the investigated 21 
instruments in the EP-9 procedure were compared with the mean of the 6 SRMPs and 22 
medical decision point analysis was performed at 48 mmol/mol (6.5%) and 75 23 
mmol/mol (9.0%). The 6 SRMPs were calibrated with IFCC secondary reference 24 
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material placing them one step higher in the traceability chain, than when using 1 
calibrators supplied by the manufacturer. 2 
 3 
IFCC monitoring program 4 
The Roche c513 and the Abbott Enzymatic were both candidates to become an 5 
official SRMP in the IFCC and the NGSP network. To become IFCC certified the 6 
methods must demonstrate traceability  to the IFCC Reference System by 7 
participation in the IFCC monitoring program. This monitoring program consists of 24 8 
interconnected samples (12 samples in duplicate). One sample is analyzed every two 9 
weeks, and the results submitted via the website. Values are assigned by all of the 10 
approved laboratories of the IFCC Network (n=21) [5]. The 24 samples from the 11 
IFCC monitoring program were analyzed in one run by the evaluated methods.   12 
 13 
Linearity 14 
Linearity was assessed using the CLSI EP-6 protocol [12]. After adjustment for Hb 15 
concentration, patient samples with a low HbA1c value (27 mmol/mol (4.6%)) and a 16 
high HbA1c value (148 mmol/mol (15.7%)) were mixed in incremental amounts to 17 
generate a series of samples over a broad HbA1c concentration range (n=11). The 18 
theoretical HbA1c value and the measured values were compared.   19 
 20 
 21 
 22 
Hemoglobin Variant Interferences 23 
Interference from common Hb-variants HbAS, HbAC, HbAD, HbAE, increased A2 (β-24 
thall) and HbF was investigated. Five samples of each variant, with different HbA1c 25 
values were analyzed in one run. The specific variants were identified using cation-26 
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exchange HPLC (Menarini HA8180V, Diabetes Mode) and capillary electrophoresis 1 
(Sebia Capillarys 2 Flex Piercing, Hemoglobin program). HbA1c values were assigned 2 
using an IFCC calibrated boronate affinity HPLC (Premier Hb9210).  3 
The percentage HbF was determined using the Sebia Capillarys 2 Flex Piercing and, 4 
HbA1c values  of the samples with HbF were assigned using an IFCC calibrated 5 
cation exchange HPLC (Menarini HA8180V, Diabetes Mode). The percentages of  6 
HbF in the 5 HbF samples were: 4.6%, 6.2%, 15.0%, 18.0% and 39.0%. The 7 
investigated Hb variant can be considered as not causing an interference if the 8 
results of the Hb variant fall within the deviation of the non-variant samples 9 
distributed around the regression line. A mean relative difference exceeding ± 10% in 10 
SI units compared to the assigned value was defined as clinical significant. 11 
Other interferences 12 
Four samples with 12.9%, 9.1%, 5.4% and 3.4% carbamylated hemoglobin were 13 
made according to a previously published method [13]. 14 
The plasma of 6 patient samples with triglyceride concentrations of 5.2, 8.1, 9.3, 15 
10.1, 14.6 and 15.6 mmol/L and plasma of 3 samples containing 164, 215 and 409 16 
µmol/L bilirubin were used to re-suspend pooled red cells from samples with an 17 
HbA1c value of approximately 48 mmol/mol (6.5%). The samples were measured in 18 
singleton together with the original pooled sample.  19 
 20 
Investigating the effect of using fresh versus frozen samples in both 21 
hemolysate and whole blood modes and sedimentation of red blood cells 22 
10 
 
Aliquots were made from 9 samples with HbA1c values ranging from, approximately, 1 
26 mmol/mol (4.5%) to 103 mmol/mol (11.6%) and stored at minus 80°C for 2 days. 2 
After 2 days hemolysates were made from the frozen samples and from the primary 3 
samples which were kept at +4°C . The same fresh whole blood samples were used 4 
to investigate the influence of sedimentation of the red blood cells whilst samples 5 
were on the analyzer awaiting analysis. The whole blood samples were thoroughly 6 
mixed before loading and analyzed (T=0). After 30, 60, 90, 120, 150 and 180 minutes 7 
the samples were analyzed again without mixing and the results were compared with 8 
the T=0 sample. All samples were analyzed in a single run (fresh whole blood using 9 
the whole blood mode, hemolysates made from both frozen blood and the whole 10 
blood samples using the hemolysate mode) and compared with each other. The 11 
student 2-tailed t-test for paired samples was used to check for statistically significant 12 
difference between the results obtained in hemolysate and the whole blood mode 13 
and at different times. A P value <0.05 was considered significant. 14 
 15 
 16 
Analytical performance criteria 17 
Sigma metrics 18 
The Total Allowable Error (TAE) for HbA1c has been set by the TF-HbA1c as a default 19 
of 5 mmol/mol (0.46% DCCT) at an HbA1c level of 50 mmol/mol (6.7% DCCT) which 20 
corresponds with a relative TAE of 10% ((5/50)*100%) in SI units (6.9% DCCT units 21 
((0.46/6.7)*100%)) with risk levels of 2σ for routine laboratories and 4σ for laboratories 22 
performing clinical trials [4]. 23 
 24 
Medical decision point analysis 25 
11 
 
When 2 methods are statistically identical, the 95% CI for each y MDP includes the 1 
corresponding x MDP. For example: 48 mmol/mol, the diagnostic cut-off value for the 2 
diagnosis of diabetes falls within  46.5 to 48.1 mmol/mol, the 95% CI around the 3 
calculated y so both methods are statistically identical. 4 
 5 
IFCC monitoring criteria 6 
The analytical performance is considered excellent if the mean deviation from the 7 
assigned value is <1.9 mmol/mol, CV < 2% and linearity >0.9950. 8 
 9 
NGSP Manufacturer Certification Criteria 10 
Thirty seven of 40 results need to be within 6% (relative) of an individual NGSP SRMP 11 
to pass certification [14]. 12 
 13 
Statistics 14 
Calculations were performed using Microsoft® Excel 2010 (Microsoft Corporation). 15 
Statistical analyses were performed using Analyse-It® (Analyse-It Software) and EP 16 
Evaluator Release 9 (Data Innovations) [15]. 17 
For the duplicates  in the IFCC monitoring program, CV was calculated with the 18 
following formula: 19 
 20 
 

CVa 
()2
n
x 2
  100%  21 
 22 
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where CVa is the analytical CV, ∆ is the difference between duplicates, n is the 1 
number of duplicates, and x  is the mean of the duplicates. 2 
Results 3 
Precision studies 4 
The imprecision results of the EP-5 protocol are detailed in Table 1.Each of the 5 
evaluated HbA1c methods had CVs <3% in SI units and <2% in NGSP units at 46 6 
mmol/mol (6.4%) and 72 mmol/mol (8.7%). 7 
Method comparisons 8 
In the EP-9 study the Roche c513 and the Tosoh G11 both had a mean bias of 9 
approximately -2 mmol/mol (0.2%) and the Abbott Enzymatic method had a mean 10 
bias of -0.5 mmol/mol (-0.05%) compared with the mean of the 6 SRMPs (Figure 1A-11 
C and ). Medical decision point analysis for the Abbott Enzymatic method at 48 12 
mmol/mol compared to the mean of the 6 SRMPs was 47.5 mmol/mol (95% CI: 47.4 13 
to 47.6) and at 75 mmol/mol 74.4 mmol/mol (74.2 to 74.5). For Roche c513 it was 14 
46.3 mmol/mol (46.1 to 46.5) and 72.1mmol/mol (71.8 to 72.4). For the Tosoh G11 it 15 
was 46.2 mmol/mol (46.1 to 46.4) and 72.4 (72.2 to 72.6). Supplemental Table 1 16 
details the results of individual method comparisons with each of the included 17 
SRMPs.  18 
Linearity and interferences 19 
All 3 methods were linear up to 140 mmol/mol (15%) (Supplemental Figure 1A-C). All 20 
three methods showed no clinically significant interference from the common Hb-21 
variants (HbAS, HbAC, HbAD, HbAE and elevated A2). HbF > 6.2% interfered with 22 
13 
 
the Abbott Enzymatic and the Roche c513 methods but not with the Tosoh G11 1 
(Figure 2A-C and supplemental Table 2).  Carbamylated Hb  up to 12.9% showed no 2 
clinically significant  interference on the Abbott Enzymatic and the Roche c513 3 
method. The Tosoh G11 showed no clinically significant interference with HbCarb of 4 
3.4% but HbCarb of 5.4% showed clinically significant interference and no results 5 
were given at an HbCarb of 9.1% and 12.9% because of a “total plate too low” flag. 6 
The three investigated methods showed no clinically significant interference of total 7 
bilirubin up to 409 µmol/L and triglycerides up to 15.6 mmol/L (Supplemental Table 8 
3). 9 
The effect of using fresh versus frozen samples in both hemolysate and whole 10 
blood modes and sedimentation of red blood cells 11 
There was no statistical difference between frozen samples and whole blood 12 
samples or samples analyzed using either the hemolysate mode or the whole blood 13 
mode. Results of samples which had been stood for 3 hours without mixing showed 14 
no statistical difference to those which were mixed just prior to analysis. 15 
(Supplemental Table 4).  16 
Analytical Performance Criteria 17 
Sigma metrics  18 
All 3 methods had a sigma> 3 using  the precision results, from the EP-5 protocol, at 19 
an HbA1c value of 46 mmol/mol (6.4%) and the bias calculated at 48 mmol/mol 20 
(6.5%) compared to the mean of the 6 SRMPs.  Sigma’s calculated using the results 21 
of the IFCC monitoring program were > 6 for all 3 methods  (Figure 3 and Table 2).  22 
Sigma’s for the Abbott Enzymatic method, compared with the 6 individual SRMPs, 23 
14 
 
ranged from 8.4 to 10.0, for the Roche c513, from 3.2 to 4.4 and for the Tosoh G11 1 
from 7.0 to 8.7 (Supplemental Table 1).  2 
Medical decision point analysis 3 
All 3 methods showed statistically significant difference at 48 mmol/mol (6.5%) and 4 
75 mmol/mol (9.0%) but clinically seen the differences were very small and therefore 5 
acceptable.  6 
 7 
IFCC monitoring criteria 8 
When using the criteria and samples of the IFCC monitoring program the 3 methods 9 
showed excellent performance with a mean deviation from the target value of <1.9 10 
mmol/mol, CV < 2.0% in SI units and linearity >0.9950. In addition, using this protocol 11 
the sigma values were > 6 for each method (Figure 3  and  Table 2). 12 
NGSP criteria 13 
All 3 methods passed NGSP manufacturer criteria compared with the 6 individual 14 
SRMPs (Supplemental Table 1). Pass/fail calculations were based on passing with 15 
74/80 samples. 16 
The 3 methods also passed the NGSP Secondary Reference Method Certification 17 
Criteria which includes precision  (EP-5) and comparison with all SRMPs in the 18 
NGSP network (data not shown) [16].  19 
 20 
 21 
15 
 
Discussion 1 
Overall, each of the three methods performed well meeting the essential 2 
performance criteria detailed by the IFCC Task Force on Implementation of HbA1c 3 
Standardization, guidance on sigma metrics targets for routine laboratories (sigma > 4 
2). The Abbott enzymatic method and the Tosoh G11 also met the more stringent 5 
criteria for methods used in clinical trials (sigma > 4). A small shift in results after 6 
some calibrations  of the Roche c513 resulted in a higher CV in EP-5 protocol and a 7 
small bias (CV was 2.0% at 46 mmol/mol, bias was  -2 mmol/mol) which may have 8 
contributed to the slightly lower sigma value observed. Sigma’s calculated from the 9 
results of IFCC monitoring program were >4 as these CV’s were not influenced by 10 
calibrations. CV has a bigger impact on the calculation of sigma than bias [17]. The 11 
Abbott Enzymatic method showed the most robust performance with minimal bias 12 
and a very stable CV even with several different calibrations and different reagent lot 13 
numbers. This is in line with results of this method in the College of American 14 
Pathologist External Quality Scheme [18].  15 
Reducing the run time for the Tosoh G11 had no influence on the analytical 16 
performance in general. However, the disadvantage of shortening the run time is that 17 
it is no longer possible to distinguish the different Hb-variants from each other as the 18 
retention times are very close to each other. Ion-exchange methods in particular 19 
have shown tendencies to show variable interferences over time due to 20 
software/reagent changes. The recent publications of Rohlfing, et. al. [19] and 21 
Lenters-Westra [20] shows this very clearly. Shortening the run time of the Tosoh 22 
G11, like all cation exchange methods, has the potential to make the instrument 23 
vulnerable to interference from Hb-variants and other substances such as 24 
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carbamylated Hb. Carbamylated Hb up to 3.4% did not interfere with the Tosoh G11 1 
but an HbCarb of 5.4% showed an clinically significant interference. This might be a 2 
problem with patients with diabetes and advanced kidney disease.  However, many 3 
patients are not allowed to become that uremic any longer so this may only be an 4 
issue in poorer and underdeveloped health systems. In addition to potential analytical 5 
interferences, such as carbHb, patients with end stage renal failure are likely to have 6 
multiple clinical factors that may affect the validity of HbA1c such as anaemia and the 7 
use of Epo, which can only be accounted for with good clinical information on the  8 
patient. The Tosoh G11 showed no clinically significant  interference with the 9 
common Hb-variants but HbAC was borderline. The mean relative difference of the 5 10 
HbAC samples was 9.6% but 2 out of the 5 HbAC samples had a difference >10%. 11 
Historically HbAE has been a problem with the Tosoh analysers but interestingly 12 
showed no interference with the Tosoh G11. This is remarkable as, unlike the HbD 13 
peak, the HbE peak does not separate from the HbA0 peak. This means that the 14 
instrument incorporates an adjustment factor, which worked with the samples we 15 
investigated but might not work with all samples containing HbAE.   16 
Whilst all methods passed the NGSP criteria for manufacturer certification (where 17 
methods are compared against one NGSP SRMP rather than the mean of all), the 18 
Abbott enzymatic method performed very well with no samples more than ±6% of the 19 
designated SRMP. The results of the Roche c513 show that it is possible to pass the 20 
manufacturer certification criteria whilst failing to meet the sigma metrics criteria ( σ > 21 
4) for laboratories engaged in clinical trials.  22 
When an offline calibration, using IFCC secondary reference materials, is applied to 23 
the results, the small shifts in results, seen with changes in manufacturer’s calibrants, 24 
are negated, resulting in sigma values >4. The IFCC secondary reference material is 25 
17 
 
one step higher in the traceability chain than the calibrators of the manufacturer and 1 
therefore more accurate. However this is not practical in a routine laboratory setting. 2 
Each of the methods included in this study are produced by manufacturers that can 3 
demonstrate traceability of their calibrators to the IFCC primary reference 4 
measurement procedure, which complies with ISO 17511:2003 standards detailing 5 
how to assure the metrological traceability of patient sample values. This also complies 6 
with WHO criteria for the diagnosis of type 2 diabetes (T2DM) using HbA1c [2].  In 7 
addition the MDP analysis at 48 mmol/mol offers reassurance to clinicians that the 8 
instruments perform well at this level. 9 
The Abbott Enzymatic method on the Architect c4000, the Roche Gen.3 HbA1c on the 10 
Cobas c513 and the Tosoh G11 were shown to perform well and are suitable for 11 
clinical application in the analysis of HbA1c. In addition, a critical aim of the study was 12 
to assess the suitability of the Abbott Enzymatic and the Roche c513 as candidate 13 
SRMPs, and based on most of the data shown here, they are now official, certified 14 
IFCC and NGSP SRMPs [5, 6].  15 
 16 
 17 
 18 
 19 
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Legends 1 
 2 
Figure 1 (A-C) 3 
HbA1c results in SI units for  (A) Abbott Enzymatic on Architect c4000, (B) Roche 4 
Gen.3 HbA1c on Cobas c513 and (C) Tosoh G11 compared to the mean HbA1c 5 
results from 6 IFCC Secondary Reference Measurement Procedures. 6 
 7 
 8 
Figure 2 (A-C) 9 
Interference from common Hb-variants (n=5 per Hb-variant) by Abbott Enzymatic (A), 10 
Roche c513 (B) and Tosoh G11 (C) 11 
 12 
 13 
Figure 3  14 
Sigma metrics results for the Abbott Enzymatic on Architect c4000 (A and AA), 15 
Roche Gen. 2 HbA1c on Cobas c513 (B and BB) and the Tosoh G11 (C and CC)) 16 
based on the CV in EP-5 at 46 mmol/mol and bias at 48 mmol/mol compared to the 17 
mean of 6 Secondary Reference measurement Procedures and (A,B and C) and the 18 
results of the IFCC monitoring program (AA, BB and CC). 19 
 20 
  21 
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Table 1 EP-5 Imprecision results   
 
     CV (%) SI units CV(%) NGSP units 
Abbott Enzymatic  
46.2 mmol/mol (6.38 % NGSP)  1.1   0.7  
71.6 mmol/mol (8.70% NGSP)  0.9    0.6  
    
Roche c513 
45.9 mmol/mol (6.35% NGSP)  2.0     1.3  
71.9 mmol/mol (8.73% NGSP)  2.1    1.5  
 
Tosoh G11  
45.8 mmol/mol (6.34% NGSP)  0.9   0.6  
69.3 mmol/mol (8.50% NGSP)  0.6    0.4  
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 Deming 
regressio
n line 
Mean 6 
SRMPs 
CV (%) 
EP-5 
HbA1c 
46 
mmol/mo
l 
Abs. 
bias at 
48 
mmol/m
ol 
Bias(%) 
at 
48 
mmol/m
ol 
σ 
(TAE= 
10%) 
Abbott 
Architect 
Enzymati
c 
 
Y=0.99X 
– 0.19 
 
1.1 
 
0.5 
 
1.0 
 
8.2 
Roche 
Cobas 
C513 TQ 
 
Y=0.96X 
+ 0.42 
 
2.0 
 
1.7 
 
3.5 
 
3.3 
 
Tosoh 
G11 
 
 
Y=0.97X 
– 0.30 
 
0.9 
 
1.8 
 
3.8 
 
6.9 
 Deming 
regressio
n line 
IFCC 
mon prog 
CV (%) 
in IFCC 
mon 
program 
Abs. 
bias at 
48 
mmol/m
ol 
Bias(%) 
at 
48 
mmol/m
ol 
σ 
(TAE= 
10%) 
Abbott 
Architect 
Enzymati
c 
 
Y=1.01X 
– 0.61 
 
0.7 
 
0.3 
 
0.6 
 
13.4 
Roche   
0.7 
 
1.7 
 
3.6 
 
9.1 
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Table 2 Sigma calculated  at 48 mmol/mol with TAE of 10% (σ=(TAE – B)/CV) using 
the method comparison results between investigated method and mean of 6 SRMPs 
and the results of the IFCC monitoring program. 
 
 
 
 
Cobas 
C513 TQ 
Y=0.99X 
– 1.23 
 
Tosoh 
G11 
 
 
Y=0.95X 
+ 1.46 
 
0.6 
 
0.9 
 
1.9 
 
13.5 
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Supplemental Table 3 Interferences 
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 TV=target value
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Supplemental Table 1 EP-9  (n=80) results in DCCT units and calculations of NGSP certification criteria 
* 37 (74) of 40 (80) results need to be within 6% (relative) of an individual NGSP SRMP to pass certification. 
 
 
Deming 
regression  
lines 
 
Mean 
Bias 
 
SEE 
 
Out    ± 
6% SRM 
NGSP 
Manfacturer 
criteria* 
 
Sigma# 
Abbott (Y)        vs Premier Isala (X) Y=0.99X + 0.04 -0.05 0.12 0 Pass 9.1 
Enzymatic       vs TQ Integra 800 Isala (X)  Y=0.99X + 0.05 -0.01 0.09 0 Pass 10.0 
                         vs Tosoh G8 Isala (X)  Y=1.01X – 0.10 -0.04 0.08 0 Pass 8.9 
                         vs Premier SKB  (X) Y=0.98X + 0.03 -0.08 0.12 0 Pass 8.4 
                         vs Menarini HA8180 SKB (X)  Y=0.99X - 0.00 -0.05 -0.06 0 Pass 9.1 
                         vs Sebia SKB (X)  Y=0.99X - 0.03 -0.06 0.11 0 Pass 8.7 
Roche (Y)        vs Premier Isala (X) Y=0.95X + 0.19 -0.18 0.15 5 Pass 3.6 
C513                vs TQ Integra 800 Isala (X) Y=0.96X + 0.18 -0.15 0.14 1 Pass 4.0 
                         vs Tosoh G8 Isala (X)   Y=0.97X + 0.06 -0.18 0.13 2 Pass 3.5 
                         vs Premier SKB  (X) Y=0.94X + 0.18 -0,21 0.14 3 Pass 3.2 
                         vs Menarini HA8180 SKB (X) Y=0,95X + 0.14 -0.18 0.13 2 Pass 3.5 
                         vs Sebia SKB (X) Y=0.96X +0.11 -0.20 0.11 1 Pass 4.4 
Tosoh  (Y)       vs Premier Isala (X) Y=0.96X + 0.10 -0.17 0.15 2 Pass 7.8 
G11                  vs TQ Integra 800 Isala (X)  Y=0.97X + 0.10 -0.14 0.10 0 Pass 8.7 
                         vs Tosoh G8 Isala (X)   Y=0.98X – 0.05 -0.17 0.05 0 Pass 7.5 
                         vs Premier SKB  (X)  Y=0.96X + 0.09 -0.21 0.15 3 Pass 7.0 
                         vs Menarini HA8180 SKB (X) Y=0.97X + 0.05 -0.17 0.07 0 Pass 7.5 
                         vs Sebia SKB (X) Y=0.97X + 0.01 -0.19 0.12 0 Pass 7.3 
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# Sigma calculated using CV of EP-5 and bias at HbA1c value of 6.5% and total allowable error of 7.0% (σ=(TAE – B)/CV). 
Supplemental Table 4 The effect of using fresh versus frozen samples in both hemolysate and whole blood modes and sedimentation of red blood cells 
 
Abbott Enzymatic Architect c4000         
           
 Hemolysate mode  Whole blood mode        
 
Frozen whole 
blood 
Fresh whole 
blood T=0 T=30 T=60 T=90 T=120 T=150 T=180  
1 26,4 26,5 25,9 26,6 26,7 26,9 26,6 26,7 26,7  
2 30,3 30,6 30,2 30,6 30,6 30,6 30,6 30,8 30,9  
3 37,3 37,3 36,0 36,9 37,0 37,3 37,2 37,2 37,3  
4 47,3 46,1 46,9 48,0 48,1 48,3 48,0 48,1 48,4  
5 59,4 59,8 59,5 60,3 60,5 60,5 60,6 60,4 60,9  
6 65,6 65,7 65,7 66,4 67,0 66,9 67,0 67,0 67,1  
7 77,9 78,9 79,5 80,8 81,2 81,3 81,4 81,3 81,5  
8 90,2 90,5 90,3 91,3 92,3 92,3 92,5 92,3 92,6  
9 103,4 103,5 104,0 104,8 105,9 105,7 106,0 106,0 106,2  
X-mean  59,7 59,9 59,8 60,6 61,0 61,1 61,1 61,1 61,3  
p value  0,99 0,99 0,95 0,93 0,92 0,92 0,92 0,91  
           
Roche Cobas c513          
           
 Hemolysate mode  Whole blood mode        
 
Frozen whole 
blood 
Fresh whole 
blood T=0 T=30 T=60 T=90 T=120 T=150 T=180 after 24 hours 
1 26,3 26,5 26,5 26,8 26,9 27,4 27,5 27,4 26,8 27,4 
2 30,4 30,9 31,2 30,9 31,1 31,3 31,5 31,6 31,5 32,0 
3 36,4 36,4 36,7 38,0 37,9 37,7 38,1 38,2 38,2 39,1 
4 46,5 46,6 47,0 49,1 49,9 50,1 49,6 50,2 49,5 50,4 
5 57,8 58,4 60,3 61,3 62,3 61,0 61,3 61,3 60,5 60,4 
6 63,4 64,5 65,4 67,9 67,9 67,8 68,4 67,2 67,6 66,2 
7 78,5 79,7 80,5 76,8 76,7 76,3 76,1 76,2 76,2 76,8 
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8 88,9 89,0 91,0 87,0 86,5 85,6 87,6 87,1 85,9 88,3 
9 100,2 101,3 102,3 99,3 98,8 100,4 99,3 99,3 100,1 114,8 
X-mean  58,7 59,3 60,1 59,7 59,8 59,7 59,9 59,8 59,6 61,7 
p value  0,97 0,95 0,97 0,98 0,98 0,99 0,98 0,97 0,90 
           
           
           
Tosoh 
G11           
           
 Hemolysate mode  Whole blood mode        
 
Frozen whole 
blood 
Fresh whole 
blood T=0 T=30 T=60 T=90 T=120 T=150 T=180  
1 23,1 23,5 23,7 23,7 23,7 22,9 23,3 22,9 23,2  
2 29,1 29,2 29,3 29,1 28,9 29,3 29,4 29,4 29,3  
3 37,0 37,6 38,8 38,6 38,2 38,4 39,0 38,7 38,5  
4 47,5 48,3 48,2 48,3 47,7 47,6 48,1 48,0 47,8  
5 57,7 58,4 58,4 58,4 58,6 58,0 58,2 58,3 58,4  
6 65,0 65,8 65,9 65,7 65,6 65,7 65,9 66,0 65,4  
7 76,8 76,9 77,4 76,6 76,5 76,9 76,6 77,0 76,7  
8 88,3 87,3 88,0 88,1 87,5 88,2 88,2 87,8 88,0  
9 99,0 99,2 98,9 99,1 99,6 99,6 99,6 99,3 99,7  
X-mean  58,2 58,5 58,7 58,6 58,5 58,5 58,7 58,6 58,6  
p value  0,98 0,98 0,99 0,98 0,99 1,00 0,99 0,99  
 
 
 
 
